Your browser doesn't support javascript.
loading
Cutaneous eruptions from ibrutinib resembling epidermal growth factor receptor inhibitor-induced dermatologic adverse events.
Singer, Sean; Tan, Sally Y; Dewan, Anna K; Davids, Matthew; LaCasce, Ann S; Treon, Steven P; LeBoeuf, Nicole R.
Affiliation
  • Singer S; Harvard Medical School, Boston, Massachusetts.
  • Tan SY; Harvard Medical School, Boston, Massachusetts; Department of Internal Medicine, Brigham & Women's Hospital, Boston, Massachusetts.
  • Dewan AK; Vanderbilt University Medical Center, Nashville, Tennessee.
  • Davids M; Center for Hematologic Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.
  • LaCasce AS; Center for Hematologic Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.
  • Treon SP; Bing Center for Waldenström's Macroglobulinemia, Dana-Farber Cancer Institute, Boston, Massachusetts.
  • LeBoeuf NR; Center for Cutaneous Oncology, Department of Dermatology, Dana-Farber/Brigham & Women's Cancer Center, Boston, Massachusetts. Electronic address: nleboeuf@partners.org.
J Am Acad Dermatol ; 88(6): 1271-1281, 2023 06.
Article in En | MEDLINE | ID: mdl-31870917

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Drug Eruptions / Exanthema Limits: Humans Language: En Journal: J Am Acad Dermatol Year: 2023 Type: Article

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Drug Eruptions / Exanthema Limits: Humans Language: En Journal: J Am Acad Dermatol Year: 2023 Type: Article